Ignite Creation Date:
2025-12-25 @ 4:11 AM
Ignite Modification Date:
2026-02-25 @ 11:03 PM
Study NCT ID:
NCT01455220
Status:
COMPLETED
Last Update Posted:
2017-03-31
First Post:
2011-10-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Sponsor:
University of South Florida
Organization:
Study Overview
Official Title:
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Tysex
Brief Summary:
The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.
Detailed Description:
Patients will be naive to Tysabri at the baseline for this study then their sexual dysfunction, fatigue, and quality of life measures will be measured using scaled questionnaires.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: